| SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition A Nelde, T Bilich, JS Heitmann, Y Maringer, HR Salih, M Roerden, ... Nature immunology 22 (1), 74-85, 2021 | 654 | 2021 |
| A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity JS Heitmann, T Bilich, C Tandler, A Nelde, Y Maringer, M Marconato, ... Nature 601 (7894), 617-622, 2022 | 234 | 2022 |
| The immunopeptidomic landscape of ovarian carcinomas H Schuster, JK Peper, HC Bösmüller, K Röhle, L Backert, T Bilich, B Ney, ... Proceedings of the National Academy of Sciences 114 (46), E9942-E9951, 2017 | 194 | 2017 |
| T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals T Bilich, A Nelde, JS Heitmann, Y Maringer, M Roerden, J Bauer, J Rieth, ... Science translational medicine 13 (590), eabf7517, 2021 | 170 | 2021 |
| The antigenic landscape of multiple myeloma: mass spectrometry (re) defines targets for T-cell–based immunotherapy S Walz, JS Stickel, DJ Kowalewski, H Schuster, K Weisel, L Backert, ... Blood, The Journal of the American Society of Hematology 126 (10), 1203-1213, 2015 | 129 | 2015 |
| Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer C Hinterleitner, J Strähle, E Malenke, M Hinterleitner, M Henning, ... Nature communications 12 (1), 7005, 2021 | 110 | 2021 |
| The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy T Bilich, A Nelde, L Bichmann, M Roerden, HR Salih, DJ Kowalewski, ... Blood, The Journal of the American Society of Hematology 133 (6), 550-565, 2019 | 77 | 2019 |
| Preexisting and post–COVID-19 immune responses to SARS-CoV-2 in patients with cancer T Bilich, M Roerden, Y Maringer, A Nelde, JS Heitmann, ML Dubbelaar, ... Cancer discovery 11 (8), 1982-1995, 2021 | 46 | 2021 |
| The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma J Bauer, N Köhler, Y Maringer, P Bucher, T Bilich, M Zwick, S Dicks, ... Nature Communications 13 (1), 6401, 2022 | 38 | 2022 |
| Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia A Nelde, Y Maringer, T Bilich, HR Salih, M Roerden, JS Heitmann, ... Frontiers in immunology 12, 705974, 2021 | 38 | 2021 |
| CXCR1 regulates pulmonary anti-pseudomonas host defense M Carevic, H Öz, K Fuchs, J Laval, C Schroth, N Frey, A Hector, T Bilich, ... Journal of innate immunity 8 (4), 362-373, 2016 | 30 | 2016 |
| Antigen targets for the development of immunotherapies in leukemia J Bauer, A Nelde, T Bilich, JS Walz International Journal of Molecular Sciences 20 (6), 1397, 2019 | 19 | 2019 |
| Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma T Bilich, A Nelde, J Bauer, S Walz, M Roerden, HR Salih, K Weisel, ... Blood cancer journal 10 (2), 24, 2020 | 18 | 2020 |
| SARS-CoV-2-reactive T cell receptors isolated from convalescent COVID-19 patients confer potent T cell effector function F Brunk, A Moritz, A Nelde, T Bilich, N Casadei, SAK Fraschka, ... European Journal of Immunology, 2021 | 11 | 2021 |
| A T-cell antigen atlas for meningioma: novel options for immunotherapy G Medici, LK Freudenmann, J Velz, SSY Wang, K Kapolou, ... Acta neuropathologica 146 (2), 173-190, 2023 | 8 | 2023 |
| Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort CM Tegeler, T Bilich, Y Maringer, HR Salih, JS Walz, A Nelde, ... International Journal of Infectious Diseases 120, 187-195, 2022 | 7 | 2022 |
| Characterization of T-cell epitopes for antigen-specific immunotherapy concepts targeting myeloproliferative neoplasms and multiple myeloma T Bilich Universität Tübingen, 2022 | 1 | 2022 |
| Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients JS Heitmann, S Jung, M Wacker, Y Maringer, A Nelde, J Bauer, M Denk, ... Frontiers in immunology 15, 1482715, 2024 | | 2024 |
Hans-Georg RammenseeProf. ImmunologyE-mail megerősítve itt: uni-tuebingen.de
